Cannabis and Stroke Study (CASS): A comparison of positive drug screens for cannabis and amphetamines in stroke versus nonstroke patients

Study comparing the proportion of positive drug screens for cannabis and amphetamines in stroke and nonstroke patients aged between 45 and 55 years

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12610000198022

Acronym

CASS

Enrollment

Registered

2010-03-09

Start date

2010-04-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The hypothesis is that cannabis and amphetamine use can precipitate stroke. The Aim is to compare the proportion of positive urine drug screens of a group of young stroke patients with a group of nonstroke patients

Interventions

Nonstroke patients aged 45- 55 years will have urine drug screen performed for cannabis and amphetamines. One urine sample drug screen at time of admisssion. Duration of study two years

Eligibility

Sex/Gender

All

Age

45 Years to 55 Years

Healthy volunteers

Inclusion criteria

age 45- 55 years admission under general medicine with diagnosis other than stroke and a urine sample taken as part of their care

Exclusion criteria

Stroke

Outcome results